Please login to the form below

Not currently logged in
Email:
Password:

Takeda to pay $2.4bn to settle Actos cancer suits

Will be one of the largest drug safety settlements in US history

Takeda HQTakeda has been ordered to pay $2.4bn to settle hundreds of law suits in the US that allege its diabetes drug Actos increases the risk of certain cancers.

Actos (pioglitazone) is licensed to help patients with type II diabetes reduce their sugar levels and has been on the market for more than 15 years.

In 2011 the FDA slapped a Black Box safety warning on the drug indicating that it can increase the risk of bladder cancer. 

Since then thousands of lawsuits have been filed against Takeda after new studies came to light showing a significant increase of risk for those patients taking Actos and being diagnosed with bladder cancer.

Sales of Actos peaked in 2011 at $4.5bn, but has since been slowly declining as new drugs have taken some market share combined with fresh concerns over its safety profile.

Actos has generated more than $16bn in sales since its 1999 release, according to court filings, but now also faces generic competition from India's Ranbaxy Laboratories.

Lilly, who was Takeda's US partner in selling and marketing the drug over seven years from 1999, have previously contended Takeda agreed to cover all legal costs stemming from its US sales, and is therefore not named in this case. 

As in common in such settlements, the Japanese firm has not admitted liability and believes the litigation is “without merit”. 

It will still, however, pay around $2.4bn into a settlement fund for the plaintiffs, and also take a $2.7bn charge against earnings it made in the fourth quarter of 2014. This works out at around $300,000 being paid out per case.

The company said it would not be pulling the medicine from other markets as a result of this week's outcome. 

The $2.4bn will be one of the largest pay outs in US history for a drug's safety, with the largest being the 2007 settlement from Merck & Co, which paid $4.85bn to settle about 30,000 lawsuits over its withdrawn painkiller Vioxx (rofecoxib).


Article by
Ben Adams

29th April 2015

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....